Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma? Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Carcinoma, Ductal, Breast
  • Carcinoma, Lobular
  • Lymph Node Excision
  • Receptor, ErbB-2
  • Receptors, Estrogen
  • Receptors, Progesterone

abstract

  • Among LORIS-eligible women, 20 % had invasive carcinoma at surgical excision that was heterogeneous in grade, size, and receptor status. Information gained from surgical excision influenced receipt of adjuvant radiation and endocrine therapy in most patients, and indicated benefit from chemotherapy in 18 % of patients. Surgical excision is warranted until additional risk stratification is available to identify a cohort of DCIS patients at lower risk for clinically significant synchronous invasive carcinoma.

publication date

  • October 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5070657

Digital Object Identifier (DOI)

  • 10.1245/s10434-016-5268-2

PubMed ID

  • 27172775

Additional Document Info

start page

  • 3487

end page

  • 3493

volume

  • 23

number

  • 11